Early safety check: how a potential liver drug moves through different bodies
NCT ID NCT06715670
Summary
This early-stage study aimed to understand how the experimental drug zibotentan is absorbed, distributed, and eliminated by the body in healthy volunteers. It involved 30 healthy Japanese and non-Asian participants who each received four different single doses of the drug over several weeks. The main goal was to measure drug levels in the blood and urine to see if there were any differences between the two ethnic groups and to check for safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Glendale, California, 91206, United States
Conditions
Explore the condition pages connected to this study.